Psoriasin (S100A7) promotes migration of a squamous carcinoma cell line

Journal of Dermatological Science

Volumn 67, Issue 3, 2012, Pages 205-207

  Winston, Jason ^a   Wolf, Ronald ^a,b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Koebnerisin; Psoriasin; S100; Tumor progression

Indexed keywords

ADVANCED GLYCATION END PRODUCT; PSORIASIN;

CANCER CELL CULTURE; CANCER GROWTH; CARCINOMA CELL; CELL MIGRATION; CONTROLLED STUDY; LETTER; MOUTH SQUAMOUS CELL CARCINOMA; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION;

CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; PHENOTYPE; S100 PROTEINS;

EID: 84864310287     PISSN: 09231811     EISSN: 1873569X     Source Type: Journal    
DOI: 10.1016/j.jdermsci.2012.06.009     Document Type: Letter

References (12)

1. Moubayed N., Weichenthal M., Harder J., Wandel E., Sticherling M., Glaser R. Psoriasin (S100A7) is significantly up-regulated in human epithelial skin tumours. J Cancer Res Clin Oncol 2007, 133:253-261.
2. Tateno T., Ueno S., Hiwatashi K., Matsumoto M., Okumura H., Setoyama T., et al. Expression of receptor for advanced glycation end products (RAGE) is related to prognosis in patients with esophageal squamous cell carcinoma. Ann Surg Oncol 2009, 16:440-446.
3. Gebhardt C., Riehl A., Durchdewald M., Nemeth J., Furstenberger G., Muller-Decker K., et al. RAGE signaling sustains inflammation and promotes tumor development. J Exp Med 2008, 205:275-285.
4. Taguchi A., Blood D.C., del Toro G., Canet A., Lee D.C., Qu W., et al. Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature 2000, 405:354-360.
5. Wolf R., Howard O.M., Dong H.F., Voscopoulos C., Boeshans K., Winston J., et al. Chemotactic activity of S100A7 (psoriasin) is mediated by the receptor for advanced glycation end products and potentiates inflammation with highly homologous but functionally distinct S100A15. J Immunol 2008, 181:1499-1506.
6. Nasser M.W., Qamri Z., Deol Y.S., Ravi J., Powell C.A., Trikha P., et al. S100A7 enhances mammary tumorigenesis through upregulation of inflammatory pathways. Cancer Res 2012, 72:604-615.
7. Choi J., Lee M.K., Oh K.H., Kim Y.S., Choi H.Y., Baek S.K., et al. Interaction effect between the receptor for advanced glycation end products (RAGE) and high-mobility group box-1 (HMGB-1) for the migration of a squamous cell carcinoma cell line. Tumori 2011, 97:196-202.
8. Dimitroulakos J., Marhin W.H., Tokunaga J., Irish J., Gullane P., Penn L.Z., et al. Microarray and biochemical analysis of lovastatin-induced apoptosis of squamous cell carcinomas. Neoplasia 2002, 4:337-346.
9. Tripathi S.C., Matta A., Kaur J., Grigull J., Chauhan S.S., Thakar A., et al. Nuclear S100A7 is associated with poor prognosis in head and neck cancer. PLoS One 2010, 5:e11939.
10. Zhou G., Xie T.X., Zhao M., Jasser S.A., Younes M.N., Sano D., et al. Reciprocal negative regulation between S100A7/psoriasin and beta-catenin signaling plays an important role in tumor progression of squamous cell carcinoma of oral cavity. Oncogene 2008, 27:3527-3538.
11. Chen D., Zheng X.F., Yang Z.Y., Liu D.X., Zhang G.Y., Jiao X.L., et al. S100A4 silencing blocks invasive ability of esophageal squamous cell carcinoma cells. World J Gastroenterol 2012, 18:915-922.
12. Wolf R., Voscopoulos C., Winston J., Dharamsi A., Goldsmith P., Gunsior M., et al. Highly homologous hS100A15 and hS100A7 proteins are distinctly expressed in normal breast tissue and breast cancer. Cancer Lett 2009, 277:101-107.